
Nurix Therapeutics, Inc.: shareholders and insiders
Price
$14.73
November 16, 2026Market cap $1.6B
What Ploutos Investor adds for Nurix Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from FY2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 33% since Oct 13, 2026, when the 10-Q these figures come from was filed ($22.13 then, $14.73 on Nov 16, 2026). The figures date from before that move.10-Q
- Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.
Insiders and their shares
Purchases and sales by officers and directors from Nov 17, 2025 to Nov 4, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$5.8M
4 people
From Nov 17, 2025 to Nov 17, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan77%
- The rest23%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 17, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $5.1M by 4 people
- 2025: no buys, sold $709.2K by 1 person
- 2026: no buys, sold $5.1M by 4 people
- Nov 4, 2026Houte Hans vanChief Financial OfficerKind10b5-1
- Nov 4, 2026Houte Hans vanChief Financial OfficerKind10b5-1
- Nov 3, 2026Christine RingChief Legal OfficerKind10b5-1
- Nov 2, 2026Christine RingChief Legal OfficerKind10b5-1
- Nov 2, 2026Christine RingChief Legal OfficerKind10b5-1
- Nov 2, 2026Christine RingChief Legal OfficerKind10b5-1
- Nov 2, 2026Gwenn HansenChief Scientific OfficerKind10b5-1
- Nov 2, 2026Gwenn HansenChief Scientific OfficerKind10b5-1
- Oct 30, 2026Houte Hans vanChief Financial OfficerKind
- Oct 30, 2026Houte Hans vanChief Financial OfficerKind
- Oct 30, 2026Houte Hans vanChief Financial OfficerKind
- Oct 30, 2026Houte Hans vanChief Financial OfficerKind
- Oct 30, 2026Christine RingChief Legal OfficerKind
- Oct 30, 2026Christine RingChief Legal OfficerKind
- Oct 30, 2026Christine RingChief Legal OfficerKind
- Oct 30, 2026Christine RingChief Legal OfficerKind
- Oct 30, 2026Gwenn HansenChief Scientific OfficerKind10b5-1
- Oct 30, 2026Gwenn HansenChief Scientific OfficerKind10b5-1
- Oct 30, 2026Gwenn HansenChief Scientific OfficerKind10b5-1
- Oct 30, 2026Gwenn HansenChief Scientific OfficerKind10b5-1
- Oct 15, 2026Gwenn HansenChief Scientific OfficerKind10b5-1
- Oct 15, 2026Gwenn HansenChief Scientific OfficerKind10b5-1
- Oct 14, 2026Julia P GregoryDirectorKind
- Oct 14, 2026Julia P GregoryDirectorKind
- Oct 2, 2026Christine RingChief Legal OfficerKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | Houte Hans vanChief Financial Officer | 10b5-1 | 3,300 | $15.38 | $50.8K | Form 4 |
| Nov 4, 2026 | Houte Hans vanChief Financial Officer | 10b5-1 | 1,469 | $16.20 | $23.8K | Form 4 |
| Nov 3, 2026 | Christine RingChief Legal Officer | 10b5-1 | 6,113 | $25.83 | $157.9K | Form 4 |
| Nov 2, 2026 | Christine RingChief Legal Officer | 10b5-1 | 5,786 | $8.72 | $50.5K | Form 4 |
| Nov 2, 2026 | Christine RingChief Legal Officer | 10b5-1 | 9,527 | $25.74 | $245.2K | Form 4 |
| Nov 2, 2026 | Christine RingChief Legal Officer | 10b5-1 | 1,075 | $26.76 | $28.8K | Form 4 |
| Nov 2, 2026 | Gwenn HansenChief Scientific Officer | 10b5-1 | 1,452 | $1.86 | $2.7K | Form 4 |
| Nov 2, 2026 | Gwenn HansenChief Scientific Officer | 10b5-1 | 1,452 | $26.80 | $38.9K | Form 4 |
| Oct 30, 2026 | Houte Hans vanChief Financial Officer | 3,750 | – | – | Form 4 | |
| Oct 30, 2026 | Houte Hans vanChief Financial Officer | 2,859 | – | – | Form 4 | |
| Oct 30, 2026 | Houte Hans vanChief Financial Officer | 3,573 | – | – | Form 4 | |
| Oct 30, 2026 | Houte Hans vanChief Financial Officer | 2,834 | $26.28 | $74.5K | Form 4 | |
| Oct 30, 2026 | Christine RingChief Legal Officer | 3,750 | – | – | Form 4 | |
| Oct 30, 2026 | Christine RingChief Legal Officer | 2,859 | – | – | Form 4 | |
| Oct 30, 2026 | Christine RingChief Legal Officer | 3,573 | – | – | Form 4 | |
| Oct 30, 2026 | Christine RingChief Legal Officer | 3,957 | $26.28 | $104.0K | Form 4 | |
| Oct 30, 2026 | Gwenn HansenChief Scientific Officer | 10b5-1 | 3,750 | – | – | Form 4 |
| Oct 30, 2026 | Gwenn HansenChief Scientific Officer | 10b5-1 | 2,859 | – | – | Form 4 |
| Oct 30, 2026 | Gwenn HansenChief Scientific Officer | 10b5-1 | 3,573 | – | – | Form 4 |
| Oct 30, 2026 | Gwenn HansenChief Scientific Officer | 10b5-1 | 3,957 | $26.28 | $104.0K | Form 4 |
| Oct 15, 2026 | Gwenn HansenChief Scientific Officer | 10b5-1 | 1,452 | $1.86 | $2.7K | Form 4 |
| Oct 15, 2026 | Gwenn HansenChief Scientific Officer | 10b5-1 | 1,452 | $25.00 | $36.3K | Form 4 |
| Oct 14, 2026 | Julia P GregoryDirector | 22.6K | $1.86 | $42.0K | Form 4 | |
| Oct 14, 2026 | Julia P GregoryDirector | 22.6K | $23.40 | $528.5K | Form 4 | |
| Oct 2, 2026 | Christine RingChief Legal Officer | 10b5-1 | 5,786 | $8.72 | $50.5K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 2, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by NRIX's officers and directors from 2021 up to November 16, 2025, 5 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- BlackRock, Inc.Share of class8.20%
- Redmile Group, LLCwith 2 more personsShare of class8.10%
- Vestal Point Capital, LPwith 1 more personShare of class7.80%
- Deep Track Capital, LPwith 2 more personsShare of class7.45%
- Baker Bros. Advisors LPwith 3 more personsShare of class7.20%
- Rubric Capital Management LPwith 1 more personShare of class6.96%
- Perceptive Advisors LLCwith 2 more personsShare of class5.30%
- T. Rowe Price Associates, Inc.Share of class5.30%
- Vanguard Capital ManagementShare of class5.03%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.20% | 6.28M | Apr 23, 2025 | 13G/A | |
| Redmile Group, LLCwith 2 more persons | 8.10% | 8.78M | Aug 14, 20262 filings since Apr 24, 2026 | 13G/A | |
| Vestal Point Capital, LPwith 1 more person | 7.80% | 8.05M | Aug 14, 20262 filings since May 15, 2026 | 13G/A | |
| Deep Track Capital, LPwith 2 more persons | 7.45% | 7.74M | Aug 14, 20265 filings since Feb 14, 2025 | 13G/A | |
| Baker Bros. Advisors LPwith 3 more persons | 7.20% | 7.53M | Feb 17, 2026 | 13G/A | |
| Rubric Capital Management LPwith 1 more person | 6.96% | 7.23M | Aug 14, 2026 | 13G | |
| Perceptive Advisors LLCwith 2 more persons | 5.30% | 5.54M | Sep 23, 2026 | 13G | |
| T. Rowe Price Associates, Inc. | 5.30% | 5.44M | Aug 14, 2026 | 13G | |
| Vanguard Capital Management | 5.03% | 5.20M | Jul 31, 2026 | 13G |
Fell to 5% or less (5)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter+9.9%
- Point72 (Cohen)In the quarter-84%
- Millennium Mgmt (Englander)In the quarter-96%
- D.E. ShawIn the quarter-46%
- AQR CapitalIn the quarter×10.9
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 1.48M | +9.9% | $36M | 0.02% |
| Point72 (Cohen) | 73.1K | -84% | $1.8M | 0.00% |
| Millennium Mgmt (Englander) | 20.9K | -96% | $500.0K | 0.00% |
| D.E. Shaw | 184.6K | -46% | $4.5M | 0.00% |
| AQR Capital | 179.5K | ×10.9 | $4.4M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 18.9% of its shares outstanding were held short, +16.7% since the report before.
- Shares held short
- 20.61M
- 18.9%
- Since the report before17.66M on Sep 30, 2026
- +16.7%
- 9.2
- 2.24M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 88%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 7.13M
- Nov 15, 2023: Shares held short 7.44M
- Nov 30, 2023: Shares held short 8.33M
- Dec 15, 2023: Shares held short 8.83M
- Dec 29, 2023: Shares held short 6.59M
- Jan 12, 2024: Shares held short 7.01M
- Jan 31, 2024: Shares held short 7.29M
- Feb 15, 2024: Shares held short 7.27M
- Feb 29, 2024: Shares held short 6.85M
- Mar 15, 2024: Shares held short 6.41M
- Mar 28, 2024: Shares held short 6.97M
- Apr 15, 2024: Shares held short 7.04M
- Apr 30, 2024: Shares held short 6.90M
- May 15, 2024: Shares held short 7.28M
- May 31, 2024: Shares held short 7.39M
- Jun 14, 2024: Shares held short 7.60M
- Jun 28, 2024: Shares held short 8.07M
- Jul 15, 2024: Shares held short 8.84M
- Jul 31, 2024: Shares held short 9.32M
- Aug 15, 2024: Shares held short 9.24M
- Aug 30, 2024: Shares held short 9.26M
- Sep 13, 2024: Shares held short 9.36M
- Sep 30, 2024: Shares held short 9.08M
- Oct 15, 2024: Shares held short 9.24M
- Oct 31, 2024: Shares held short 9.46M
- Nov 15, 2024: Shares held short 9.60M
- Nov 29, 2024: Shares held short 9.35M
- Dec 13, 2024: Shares held short 9.83M
- Dec 31, 2024: Shares held short 10.79M
- Jan 15, 2025: Shares held short 10.87M
- Jan 31, 2025: Shares held short 10.95M
- Feb 14, 2025: Shares held short 11.36M
- Feb 28, 2025: Shares held short 11.60M
- Mar 14, 2025: Shares held short 12.17M
- Mar 31, 2025: Shares held short 12.16M
- Apr 15, 2025: Shares held short 14.39M
- Apr 30, 2025: Shares held short 13.69M
- May 15, 2025: Shares held short 14.12M
- May 30, 2025: Shares held short 14.09M
- Jun 13, 2025: Shares held short 14.44M
- Jun 30, 2025: Shares held short 14.07M
- Jul 15, 2025: Shares held short 13.95M
- Jul 31, 2025: Shares held short 13.03M
- Aug 15, 2025: Shares held short 12.88M
- Aug 29, 2025: Shares held short 12.81M
- Sep 15, 2025: Shares held short 13.05M
- Sep 30, 2025: Shares held short 13.04M
- Oct 15, 2025: Shares held short 13.87M
- Oct 31, 2025: Shares held short 13.12M
- Nov 14, 2025: Shares held short 14.08M
- Nov 28, 2025: Shares held short 14.49M
- Dec 15, 2025: Shares held short 13.64M
- Dec 31, 2025: Shares held short 14.64M
- Jan 15, 2026: Shares held short 15.20M
- Jan 30, 2026: Shares held short 14.96M
- Feb 13, 2026: Shares held short 15.25M
- Feb 27, 2026: Shares held short 15.97M
- Mar 13, 2026: Shares held short 16.18M
- Mar 31, 2026: Shares held short 18.13M
- Apr 15, 2026: Shares held short 19.20M
- Apr 30, 2026: Shares held short 19.20M
- May 15, 2026: Shares held short 18.63M
- May 29, 2026: Shares held short 19.32M
- Jun 15, 2026: Shares held short 20.02M
- Jun 30, 2026: Shares held short 17.80M
- Jul 15, 2026: Shares held short 17.98M
- Jul 31, 2026: Shares held short 18.35M
- Aug 14, 2026: Shares held short 17.98M
- Aug 31, 2026: Shares held short 17.95M
- Sep 15, 2026: Shares held short 17.98M
- Sep 30, 2026: Shares held short 17.66M
- Oct 15, 2026: Shares held short 20.61M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading28.8% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 28.8% of the shares in the reported trades were short sales, against 46.2% in the 14 before.
- Last 14 sessionsOct 28, 2026 – Nov 16, 2026
- 28.8%
- The 14 beforeOct 8, 2026 – Oct 27, 2026
- 46.2%
- Change
- -17.4 pts
- Short sales a dayon average, of 1.46M shares
- 420.0K
- More than atof 3,668 US-listed companies, same days
- 4%
- Median of alleight in ten from 34.7% to 63.8%
- 50.3%
- Short sales
- Oct 8, 2026: Short sales 55.6%
- Oct 9, 2026: Short sales 43.5%
- Oct 12, 2026: Short sales 46%
- Oct 13, 2026: Short sales 58.7%
- Oct 14, 2026: Short sales 57.1%
- Oct 15, 2026: Short sales 40.9%
- Oct 16, 2026: Short sales 54.4%
- Oct 19, 2026: Short sales 38.5%
- Oct 20, 2026: Short sales 27.8%
- Oct 21, 2026: Short sales 34.8%
- Oct 22, 2026: Short sales 49.4%
- Oct 23, 2026: Short sales 53.7%
- Oct 26, 2026: Short sales 43.2%
- Oct 27, 2026: Short sales 56.8%
- Oct 28, 2026: Short sales 29.8%
- Oct 29, 2026: Short sales 48.8%
- Oct 30, 2026: Short sales 40.8%
- Nov 2, 2026: Short sales 39.3%
- Nov 3, 2026: Short sales 40.2%
- Nov 4, 2026: Short sales 19.3%
- Nov 5, 2026: Short sales 23%
- Nov 6, 2026: Short sales 33%
- Nov 9, 2026: Short sales 41.1%
- Nov 10, 2026: Short sales 36.8%
- Nov 11, 2026: Short sales 32.5%
- Nov 12, 2026: Short sales 55.7%
- Nov 13, 2026: Short sales 46.1%
- Nov 16, 2026: Short sales 37.3%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Gwenn HansenChief Scientific OfficerDirectly123.5K
- Houte Hans vanChief Financial OfficerDirectly42.7K
- Julia P GregoryDirectorDirectly10.8K
- Christine RingChief Legal OfficerDirectly4,406
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Gwenn HansenChief Scientific Officer | 123.5K | – | Nov 2, 2026 | Form 4 |
| Houte Hans vanChief Financial Officer | 42.7K | – | Nov 4, 2026 | Form 4 |
| Julia P GregoryDirector | 10.8K | – | Oct 14, 2026 | Form 4 |
| Christine RingChief Legal Officer | 4,406 | – | Nov 3, 2026 | Form 4 |
A lower bound: it counts only the 4 officers and directors with a market trade since Nov 18, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 269 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- ARKGARK Genomic Revolution ETFWeight in the fund2.51%
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.56%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.39%
- IBBiShares Biotechnology ETFWeight in the fund0.19%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.11%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.08%
- IWMiShares Russell 2000 ETFWeight in the fund0.07%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.05%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.03%
- VXFVanguard Extended Market Index FundWeight in the fund0.03%
18 of the 269 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 173
- Q4 2025: Managers 182
- Q1 2026: Managers 197
- Q2 2026: Managers 211
Institutional investors by quarter
The fund managers holding NRIX, quarter by quarter, from Q3 2020 to Q2 2025, 20 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 211 managers held 117M shares, worth $2.8B. During the quarter 47 opened a position, 33 closed one, 65 added and 61 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter-1.7%
- Vestal Point CapitalIn the quarter+24%
- Deep Track CapitalIn the quarter+22%
- Rubric Capital ManagementIn the quarter+192%
- FMRIn the quarter-1.0%
- Price T Rowe AssociatesIn the quarter+65%
- Morgan StanleyIn the quarter-3.4%
- State StreetIn the quarter-9.0%
- Baker Bros. AdvisorsIn the quarter
- Vanguard Capital ManagementIn the quarter+1.5%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 8.77M | -1.7% | $213M |
| Vestal Point Capital | 8.05M | +24% | $195M |
| Deep Track Capital | 7.74M | +22% | $188M |
| Rubric Capital Management | 7.23M | +192% | $175M |
| FMR | 5.49M | -1.0% | $133M |
| Price T Rowe Associates | 5.44M | +65% | $132M |
| Morgan Stanley | 4.76M | -3.4% | $116M |
| State Street | 4.68M | -9.0% | $113M |
| Baker Bros. Advisors | 4.66M | $113M | |
| Vanguard Capital Management | 4.50M | +1.5% | $109M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Nurix Therapeutics's filings show?
Who buys and sells is one part of Nurix Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have NRIX's insiders bought or sold?
From Jun 2, 2026 to Nov 4, 2026 Nurix Therapeutics's insiders bought 0 and sold $3.7M of shares on the market. 75% of the sales were under set 10b5-1 plans.
Which well-known managers hold NRIX?
5 of the managers we track held the shares on Jun 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $36M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.